Norepinephrine Sopharma (Noradrenaline Tartrate)

Norepinephrine, the active ingredient in Norepinephrine Sopharma, is a sympathomimetic presented as an injectable solution for intravenous use. It is employed to raise blood pressure and improve cardiac output in patients with acute hypotension, septic shock, or cardiac arrest.

GNH USA supplies Norepinephrine Sopharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing EU‑sourced quality for emergency and critical care environments. The product is distributed under strict temperature‑controlled logistics to maintain stability.

Norepinephrine is a sympathomimetic vasopressor used in critical care to support circulatory function.

- Hypotension: Increases systemic vascular resistance to raise blood pressure in patients with acute low blood pressure. - Septic shock: Restores vascular tone and improves perfusion during severe sepsis‑induced hypotension. - Cardiac arrest: Provides immediate vasoconstriction to augment coronary and cerebral perfusion during resuscitation.

Norepinephrine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Tachycardia: Elevated heart rate due to beta‑1 stimulation. - Headache: Resulting from rapid changes in blood pressure. - Anxiety or restlessness: Central nervous system response to adrenergic activity. - Nausea or vomiting: Gastrointestinal irritation. - Peripheral ischemia: Reduced blood flow to extremities at high doses.

Serious or Rare Side Effects: - Severe hypertension: Excessive vasoconstriction leading to organ damage. - Myocardial ischemia or infarction: Increased cardiac workload. - Life‑threatening arrhythmias: Ventricular tachycardia or fibrillation. - Tissue necrosis at infusion site: Extravasation injury. - Pulmonary edema: Fluid accumulation due to increased afterload.

When using Norepinephrine, careful monitoring and specific precautions are essential to ensure patient safety.

- Dose titration: Adjust infusion rate to achieve target blood pressure while avoiding excessive vasoconstriction. - Cardiovascular monitoring: Continuous ECG and arterial pressure monitoring are required during therapy. - Risk of ischemia: Use caution in patients with peripheral vascular disease or compromised limb perfusion. - Drug interactions: Review concomitant vasoactive agents to prevent additive hypertensive effects. - Pregnancy: Use only if the potential benefit justifies the potential risk; category is unknown. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Norepinephrine can interact with several drug classes, influencing its efficacy and safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): May precipitate severe hypertensive crisis. - Ergot alkaloids: Combined use can cause profound vasoconstriction and ischemia. - Tricyclic antidepressants: Potentiate pressor effects, increasing risk of hypertension.

Moderate Interactions (Monitor Closely): - Other vasopressors (e.g., phenylephrine, vasopressin): May require dose adjustments to avoid excessive blood pressure. - Beta‑blockers: Can blunt beta‑1 mediated cardiac effects, altering response. - ACE inhibitors or ARBs: May affect vascular tone and require careful blood pressure monitoring.